Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Neumann, F.-J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Neumann, F.-J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Optimization of microvascular reperfusion in acute myocardial infarction

F.-J. Neumann*

Medizinische Klinik der Technischen Universität, München, Germany

* Correspondence: Franz-Josef Neumann, MD, 1 Medizinische Klinik der Technischen Universität, Ismaningerstrasse 22, 81675 München, Germany.

Abstract

Variations in flow within the spectrum of Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow determine the recovery of contractile function in the infarct zone after acute myocardial infarction (MI). The limitation of microvascular reperfusion associated with such impairment may be attributable to a variety of factors, including distal embolization of small platelet aggregates and direct interactions among platelets, leukocytes and the endothelium. Activated platelets adhere to the endothelium and modulate chemotactic and adhesive properties of endothelial cells; they also bind with leukocytes and induce up-regulation of the Mac-1 integrin, promoting endothelial adherence and elaboration of inflammatory cytokines. Mac-1 activity and platelet-leukocyte interactions are increased in patients with acute MI. The platelet glycoprotein IIb/IIIa receptor inhibitor abciximab may improve microcirculatory function by reducing distal embolization of platelet aggregates and decreasing platelet leukocyte interactions. Recent studies in patients undergoing coronary stenting for acute MI have demonstrated that abciximab is associated with significant decreases in platelet leukocyte interactions and Mac-1 expression compared with standard heparin. In a randomized trial of abciximab versus standard heparin in acute MI patients undergoing stenting, abciximab treatment was associated with significant improvements in peak flow velocity and measures of contractile function, including wall motion index and numbers of hypokinetic chords in the infarct zone and global ejection fraction. These benefits were accompanied by a significant reduction in early cardiovascular events. In addition to maintaining large-vessel patency, abciximab improves recovery of microcirculatory perfusion and contractile function in acute MI.

Key Words: Acute MI • perfusion • TIMI grade 3 • abciximab • microvascular • epicardial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.